Paratek Pharmaceuticals (PRTK) Releases Earnings Results, Misses Expectations By $0.16 EPS

Share on StockTwits

Paratek Pharmaceuticals (NASDAQ:PRTK) announced its earnings results on Tuesday. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.16), Fidelity Earnings reports. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $5.89 million. Paratek Pharmaceuticals had a negative net margin of 1,961.41% and a negative return on equity of 106.39%.

PRTK stock traded up $0.75 during midday trading on Wednesday, reaching $7.73. The company had a trading volume of 1,835,400 shares, compared to its average volume of 649,092. The company has a market cap of $237.65 million, a PE ratio of -2.34 and a beta of 0.74. Paratek Pharmaceuticals has a 1-year low of $6.27 and a 1-year high of $22.45. The company has a quick ratio of 7.88, a current ratio of 7.88 and a debt-to-equity ratio of 2.37.

In related news, Chairman Michael Bigham sold 16,313 shares of the business’s stock in a transaction dated Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total value of $160,193.66. Following the completion of the transaction, the chairman now owns 213,480 shares of the company’s stock, valued at $2,096,373.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Evan Loh sold 5,200 shares of the business’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $8.96, for a total value of $46,592.00. Following the completion of the transaction, the chief operating officer now directly owns 294,425 shares of the company’s stock, valued at approximately $2,638,048. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,446 shares of company stock valued at $559,369. 6.20% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of PRTK. Highland Capital Management LP raised its stake in Paratek Pharmaceuticals by 99.9% during the second quarter. Highland Capital Management LP now owns 1,917,878 shares of the specialty pharmaceutical company’s stock worth $19,562,000 after acquiring an additional 958,600 shares in the last quarter. BlackRock Inc. raised its stake in Paratek Pharmaceuticals by 27.3% during the second quarter. BlackRock Inc. now owns 2,583,390 shares of the specialty pharmaceutical company’s stock worth $26,350,000 after acquiring an additional 554,545 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Paratek Pharmaceuticals during the second quarter worth about $3,629,000. Granahan Investment Management Inc. MA acquired a new position in Paratek Pharmaceuticals during the second quarter worth about $1,801,000. Finally, California Public Employees Retirement System acquired a new position in Paratek Pharmaceuticals during the first quarter worth about $1,565,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have recently issued reports on PRTK shares. Guggenheim set a $26.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 3rd. Wedbush set a $20.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 target price on shares of Paratek Pharmaceuticals in a research report on Thursday, August 2nd. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Wednesday, July 25th. Finally, Bank of America started coverage on shares of Paratek Pharmaceuticals in a research report on Monday, August 27th. They issued a “neutral” rating and a $13.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Paratek Pharmaceuticals presently has an average rating of “Hold” and an average price target of $30.29.

WARNING: This report was reported by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://weekherald.com/2018/11/07/paratek-pharmaceuticals-prtk-releases-earnings-results-misses-expectations-by-0-16-eps.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

See Also: What is the Rule of 72?

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply